The Conversation (0)
BriaCell announced the dosing of the first patient for a phase I/II trial on BriaVax.
BriaCell (TSXV:BCT, OTCQB:BCTXF) announced the dosing of the first patient for a phase I/II trial on BriaVax.
As quoted in the press release:
“We are delighted to announce formal commencement of the Phase I/IIa trial of BriaVax™, a significant milestone for our promising platform technology and program,” commented Dr. Bill Williams, President & CEO of BriaCell. “We expect this study to confirm the robust safety profile of BriaVax™ previously observed in two preliminary Phase I trials in advanced breast cancer patients, as well as preliminary efficacy signals.”
“The initiation of this clinical trial brings us one step closer to provide a promising safe alternative to existing treatment options,” stated Dr. Charles Wiseman, BriaCell’s scientific founder. “We look forward to providing a targeted immunotherapy that has the capability to expand into additional solid tumors, which can also be combined with other treatment agents.”
“We are co-developing a diagnostic, BriaDx™, in parallel with the Phase I/IIa study, which we believe will ultimately assist in identifying the patients most likely to benefit from treatment with BriaVax™,” stated Dr. Markus Lacher, Head of Research and Development at BriaCell. “I am very optimistic that this clinical study — together with our already obtained excellent preliminary data — will provide us with the results necessary to complete the first version of BriaDx™ and prepare it for validation in future clinical trials, potentially opening a path for accelerated clinical development of BriaVax™.”
Click here to read the full press release.
Source: www.marketwired.com